千金药业：拟购买千金湘江药业28.92%、千金协力药业68.00%的股权

Core Viewpoint - The company plans to acquire a 28.92% stake in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and a 68.00% stake in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of share issuance and cash payment, with a total transaction price of 623 million yuan [1] Group 1 - The share issuance price is set at 8.41 yuan per share, based on the resolution announcement date of the company's 11th Board of Directors' 9th meeting on September 7, 2024 [1] - Following the completion of the transaction, the company's total share capital will increase to 495 million shares [1] - The direct shareholding ratio of the controlling shareholder, Zhuzhou Guotou, will rise to 34.11%, while the actual controller remains the Zhuzhou State-owned Assets Supervision and Administration Commission [1]